Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2018 | Cell-extrinsic biomarkers for CLL: immunogenetic data

Andreas Agathangelidis • 25 Oct 2018
ERIC 2018
Chronic Lymphocytic Leukemia Leukemia

Cell-extrinsic biomarkers for chronic lymphocytic leukemia (CLL) have a number of advantages. Here, Andreas Agathangelidis, PhD, of the Center for Research and Technology Hellas, Thermi, Greece, discusses cell-extrinsic biomarkers in CLL and what their role is in the management of the disease. Dr Agathangelidis highlights the importance of testing for immunoglobulin gene somatic hypermutation status in both routine practice and clinical trials. This interview took place at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.

More from Andreas Agathangelidis

1:24
The interplay between genetic and environmental factors in MBL
Andreas Agathangelidis • 6 Oct 2022
0:36
The use of AI for analyzing genetic and molecular data in CLL
Andreas Agathangelidis • 6 Oct 2022
0:58
Updates on the ERIC recommendations for immunoglobulin gene sequence analysis in CLL
Andreas Agathangelidis • 6 Oct 2022
0:53
Clinical significance of Ig gene mutations in CLL
Andreas Agathangelidis • 6 Oct 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals